Previous and current research
Vascular endothelial cells form the inner lining of all blood vessels and
play a critical role in various physiological and pathological processes, including
embryogenesis, tumor growth, diabetic retinopathy, and wound healing. My group
is studying the cell biology and genetics of blood vessel formation and remodeling,
both in the mouse embryo and in tumors. Specifically, we are trying to understand
how endothelial signalling systems and transcriptional regulators control the
function of endothelial cells and their interaction with the surrounding tissue.
Our previous studies have contributed to the identification of vascular endothelial
growth factor (VEGF) as a key regulator of early stage vascular development.
VEGF has also an essential function in brain angiogenesis and development,
by stimulating the sprouting of capillaries, by guiding their growth in the
neural tissue, and possibly also by acting directly on neural cells. We have
also studied endothelial cell intrinsic regulatory mechanisms of endothelial
growth and differentiation. Our data support a model in which vascular development
and angiogenesis is controlled by the combinatorial activity of members of
the Ets family of transcription factors and by hypoxia-inducible factors (HIF).
Many regulatory pathways that control physiological angiogenesis are also active
in tumors and represent therefore potential targets for therapeutic intervention.
Future prospects and goals
The development of the vascular system is intimately linked with the differentiation
of organs and tissues. In the future, we will try to understand how endothelial
signalling systems coordinate the interaction between vascular endothelial
cells and neural tissue. Transgenic and knockout animals in which the expression
of these proteins is altered will be used to study the function of these signalling
systems in vivo. Likewise, we will study the function of HIF family members
and of other proteins involved in oxygen sensing, in endothelial cell differentiation,
degeneration, regeneration and function.
Selected publications
Licht AH, Muller-Holtkamp F, Flamme I, Breier G (2006): Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood 107: 584-590.
Mitola S, Brenchio B, Piccinini M, Tertoolen L, Zammataro L, Breier G, Rinaudo MT, den Hertog J, Arese M, Bussolino F (2006): Type I Collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism. Circ Res 98:45-54.
Raab S, Beck H, Gauman A, Yuce A, Gerber HP, Plate KH, Hammes HP, Ferrara N,
Breier G (2004): Impaired brain angiogenesis and neuronal apoptosis induced by
conditional homozygous inactivation of vascular endothelial growth factor. Thromb
Haemost 91: 595-605.
Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate
KH, Siewecke M, Breier G, Flamme I (2003): Cooperative interaction of hypoxia-inducible
factor-2a and Ets-1 in the transcriptional activation of Flk-1. J Biol Chem 278:
7520-7530.
Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC,
Menger MD, and Breier G (2002): Microtumor growth initiates angiogenic sprouting
with simultaneous expression of VEGF, VEGF-receptor-2, and angiopoietin-2. J
Clin Invest 109: 777-785.
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig
M, Vandenhoeck A, Harpal K, Eberhardt C, Declerq C, Pawling J, Moons L, Collen
D, Risau W, Nagy A (1996): Abnormal blood vessel development and lethality in
embryos lacking a single VEGF allele. Nature 380: 435-439.
|  |

Georg Breier
1988: PhD, University of Heidelberg, Germany
1988-1992: Postdoctoral fellow and Research associate at the Max Planck Institute of Neurobiology, Martinsried, Germany
1993-2003: Group leader at the Max Planck Institute for Physiological and Clinical Research, Bad Nauheim, Germany
since 2003: Research Professor at the Institute of Pathology at the Medical Faculty, Dresden University of Technology
|